Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Nutex Health, Inc.
NUTX
NASDAQ·Healthcare·Medical - Healthcare Information Services·Mkt cap $1.1B
$196.53
▲ +3.05%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$77.21 - $201.49
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 56.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary cloud-based technology platform enabling integrated data analytics across multiple healthcare settings
- Dual-revenue model combining facility operations with management services and population health contracts
- Established network of 21 owned and operated facilities providing operational scale and referral relationships
- Micro-hospital expertise in underserved markets with lower capital requirements than traditional hospitals
Bear Case
2 risks
- High volatility (beta 2.1). Larger-than-normal price swings expected.
- Growth premium of 0.5x vs Healthcare IT & Services peers. Reasonable for this growth rate.
Growth
Stable outlook
Expansion of micro-hospital footprint in high-demand, underserved markets
Value
Growth premium of 0.5x vs Healthcare IT & Services peers. Reasonable for this growth rate.
Momentum
Hot
+89.0% over 3m
Quality
Strong
High-growth business (41% revenue growth, 47% gross margin). Profitable with strong growth momentum.
Dividend
None
No dividend
Smart-money signal
Who's buying NUTX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 4, 2026
APR 30, 2026
Reported EPS of $6.52 vs $3.99 consensus (+63.4% surprise). Revenue of $216.5M vs $227.8M expected (-5.0%).
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+63.4%
Next: May 4, 2026
Revenue trend · last 8Q
—
—
+270%
+214%
+221%
+240%
-41%
+2%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$76.1M
$78.8M
$257.6M
$211.8M
$244.0M
$267.8M
$151.7M
$216.5M
Margins · last 8Q
Gross
—
Operating
—
Profit
21.6%
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
$235.00
▲ +19.6% vs $196.53
Latest: B. Riley · Jun 26, 2026
1 analyst covering